Literature DB >> 8707737

Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis.

J D Cartledge1, J Midgley, B G Gazzard.   

Abstract

The growth of 113 Candida spp. isolated prospectively from 104 HIV-positive patients treated for thrush was determined using a single concentration of 3 mg/L (10(-5) M) fluconazole relative to growth in drug free medium. Using a receiver operator characteristic curve, a relative growth in fluconazole of > or = 88% best discriminated between isolates from 56 patients who responded to treatment with fluconazole and 48 who failed to respond to 7 days, treatment with at least 100 mg/d drug with a sensitivity of 98% and a specificity of 96%. When the isolates from the eight patients with mixed infections due to both resistant and susceptible yeasts were excluded, the sensitivity and specificity both reached 100%. Relative growth of Candida spp. in a single concentration of fluconazole can therefore be used to accurately predict the clinical response to standard fluconazole treatment of thrush in patients infected with HIV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707737     DOI: 10.1093/jac/37.2.275

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes.

Authors:  A Schoofs; F C Odds; R Colebunders; M Ieven; L Wouters; H Goossens
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study.

Authors:  J D Cartledge; J Midgley; B G Gazzard
Journal:  Genitourin Med       Date:  1997-12

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.